Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States

Abstract Aims The goal of this observational, single‐cohort, pre‐post study was to describe the association of tirzepatide with glycaemic control and weight loss in patients with type 2 diabetes (T2D) in a US commercially insured population. Materials and Methods Using the Healthcare Integrated Research Database (HIRD®), members ≥18 years, diagnosed with T2D, initiating tirzepatide between 13 May 2022 and 31 January 2023, with ≥1 glycated haemoglobin (HbA1c) result around the index date and the end of the 6‐month follow‐up period were identified. Baseline demographics and antihyperglycaemic medication use and key outcomes (HbA1c and weight) at 6‐month follow‐up were assessed overall and in subgroups stratified by baseline glucagon‐like peptide‐1 (GLP‐1) receptor agonist (RA) use and HbA1c (<7% and ≥7%) level. Results The cohort of 2247 identified patients was primarily non‐Hispanic White, female (58%), 54 years old, 54% had GLP‐1 RA at baseline, 59% had an HbA1c ≥7% at baseline and 61% had overweight/obesity. At 6‐month follow‐up, a majority of the cohort (69%) had an HbA1c <7%, which was higher (77%) in the GLP‐1 RA naïve subgroup. Mean change in weight was: −6.3 kg for the overall cohort; −7.1 kg in patients with baseline HbA1c <7%; and −8.1 kg in the GLP‐1 RA naïve subgroup. Conclusion In this observational, single‐cohort study, at 6‐month follow‐up, patients with T2D initiating tirzepatide showed HbA1c and weight reductions; more pronounced HbA1c reductions occurred in GLP‐1 RA naïve patients or those with baseline HbA1c ≥7%, while more weight loss was observed among GLP‐1 RA naïve patients or those with baseline HbA1c <7%.